Case studies

• 505(b)(2) NDA and MAA for Orally Disintegrating Tablet 105 Kb

• CMC and Global Regulatory Support for Generic Tablet 130 Kb

• Complete Response Letter Resolution and NDA Amendment 167 Kb

• Design of API Manufacturing Facility 100 Kb

• Global Drug Development Strategy and Special Protocol Assessments 155 Kb

• Global Regulatory Support for IV and IM Formulations 144 Kb

• PAI Audit in China 111 Kb